Catalyst Pharmaceuticals Management

Management criteria checks 2/4

Catalyst Pharmaceuticals' CEO is Rich Daly, appointed in Jan 2024, has a tenure of less than a year. directly owns 0.18% of the company’s shares, worth €2.99M. The average tenure of the management team and the board of directors is 3.4 years and 11.4 years respectively.

Key information

Rich Daly

Chief executive officer

US$14.1m

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.2%
Management average tenure	3.4yrs
Board average tenure	11.4yrs

Recent management updates

Recent updates

CEO

Rich Daly (62 yo)

less than a year

Tenure

US$14,076,923

Compensation

Mr. Richard John Daly, also known as Rich, MBA, had been an Independent Director at Catalyst Pharmaceuticals, Inc. from February 2015 until January 1, 2024 and serves as its Chief Executive Officer and Dir...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Richard John Daly	President	less than a year	US$14.08m	0.18% $ 3.0m
Steven Miller	Executive VP	14.6yrs	US$3.40m	0.70% $ 11.6m
Gary Ingenito	Chief Medical & Regulatory Officer	8.9yrs	US$2.37m	0.049% $ 808.4k
Jeffrey Del Carmen	Executive VP & Chief Commercial Officer	3.9yrs	US$2.51m	0.022% $ 366.2k
Michael Kalb	Executive VP	less than a year	no data	no data
Mary Coleman	VP & Head of Investor Relations	2.8yrs	no data	no data
Brian Elsbernd	Chief Compliance Officer & Chief Legal Officer	8.3yrs	US$353.27k	0.11% $ 1.8m
Pete Curry	Vice President of Sales	3.9yrs	no data	no data
Stanley Iyadurai	Senior Vice President of Medical Affairs & Drug Discovery	1.2yrs	no data	no data
Preethi Sundaram	Chief Strategy Officer	2.8yrs	US$1.70m	0.022% $ 360.2k
Philip Schwartz	Corporate Secretary	no data	no data	no data

3.4yrs

Average Tenure

60yo

Average Age

Experienced Management: CN2's management team is considered experienced (3.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Richard John Daly	President	9.3yrs	US$14.08m	0.18% $ 3.0m
David Tierney	Independent Director	21.6yrs	US$370.99k	0.30% $ 4.9m
Patrick McEnany	Co-Founder & Chairman	22.3yrs	US$2.15m	3.84% $ 63.9m
Donald Denkhaus	Independent Director	9.3yrs	US$376.24k	0.37% $ 6.2m
Charles O'Keeffe	Lead Independent Director	19.4yrs	US$397.24k	0.58% $ 9.7m
Eugene Laska	Member of Scientific Advisory Board	no data	no data	no data
Robert Fechtner	Member of Scientific Advisory Board	no data	no data	no data
Jonathan Brodie	Chairman of Scientific Advisory Board	no data	no data	no data
Molly Harper	Independent Director	2.9yrs	US$363.12k	0.0045% $ 75.2k
Richard Silverman	Member of Scientific Advisory Board	13.5yrs	no data	no data
Tamar Thompson	Independent Director	less than a year	US$610.43k	no data

11.4yrs

Average Tenure

62yo

Average Age

Experienced Board: CN2's board of directors are seasoned and experienced ( 11.4 years average tenure).

Catalyst Pharmaceuticals Management

Management criteria checks 2/4

Key information

Recent management updates

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Insider recently sold €380k worth of stock

COO & Chief Scientific Officer recently sold €528k worth of stock

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Recent updates

Catalyst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Insider recently sold €380k worth of stock

Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (Dmd)

Investor sentiment improves as stock rises 15%

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Full year 2023 earnings released: EPS: US$0.67 (vs US$0.80 in FY 2022)

Catalyst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Catalyst Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Investor sentiment improves as stock rises 17%

Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo Pharma

COO & Chief Scientific Officer recently sold €528k worth of stock

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.29 loss per share (vs US$0.22 profit in 3Q 2022)

Catalyst Pharmaceuticals, Inc. Receives Two New U.S. Patent Allowances for FIRDAPSE

New minor risk - Share price stability

Catalyst Pharmaceuticals, Inc. Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

Catalyst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Catalyst Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Catalyst Pharmaceuticals, Inc. Announces FDA Acceptance of the Supplemental New Drug Application for Firapse

Catalyst Pharmaceuticals, Inc. Announces the Resignation of Philip H. Coelho as Independent Member of the Board

Catalyst Pharmaceuticals, Inc. Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to Be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.21 in 2Q 2022)

Catalyst Pharmaceuticals, Inc. Announces Resignation of Patrick J. Mcenany as Chief Executive Officer

Catalyst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Catalyst Pharmaceuticals, Inc., Annual General Meeting, Aug 22, 2023

Investor sentiment improves as stock rises 15%

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

Investor sentiment deteriorates as stock falls 28%

First quarter 2023 earnings released: EPS: US$0.28 (vs US$0.13 in 1Q 2022)

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2023

Catalyst Pharmaceuticals, Inc. Advances sNDA Submission Plans to Increase Indicated Maximum Dose for FIRDAPSE®? from 80 Mg Per Day to 100 Mg Per Day

Full year 2022 earnings released: EPS: US$0.80 (vs US$0.38 in FY 2021)

Catalyst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 15, 2023

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Independent Director recently sold €321k worth of stock

Third quarter 2022 earnings released: EPS: US$0.22 (vs US$0.10 in 3Q 2021)

Catalyst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Catalyst Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for Firdapse(R) Expanding Patient Population to Include Pediatric Patients

Chief Accounting Officer recently sold €734k worth of stock

Co-Founder recently sold €16m worth of stock

Investor sentiment improved over the past week

Chief Accounting Officer recently sold €970k worth of stock

Chief Commercial Officer recently sold €198k worth of stock

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: US$0.21 (vs US$0.12 in 2Q 2021)

Catalyst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Catalyst Pharmaceuticals, Inc., Annual General Meeting, Sep 19, 2022

Catalyst Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Investor sentiment improved over the past week

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2022

First quarter 2022 earnings released: EPS: US$0.13 (vs US$0.074 in 1Q 2021)

Catalyst Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 10, 2022

Catalyst Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 16, 2022

Catalyst Pharmaceuticals, Inc. Further Strengthens FIRDAPSE® U.S. Patent Portfolio

Catalyst Pharmaceuticals, Inc. Further Strengthens FIRDAPSE® U.S. Patent Portfolio

Investor sentiment improved over the past week

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2022

Catalyst Pharmaceuticals Reports the FDA Marketing Approval Previously Granted for Ruzurgi® Is No Longer Valid

Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of A Phase 3 Study for Firdapse® (Amifampridine) in Japan

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS US$0.10 (vs US$0.42 in 3Q 2020)

Investor sentiment improved over the past week

Chief Accounting Officer recently sold €63k worth of stock